Adare Pharma Solutions Relocates Global Headquarters to Philadelphia, Expands Manufacturing Facilities with State Support
Adare Pharma Solutions relocates its global headquarters to Philadelphia and expands its manufacturing facilities with the support of Pennsylvania’s Department of Community and Economic Development, creating 115 new jobs and reinforcing the state’s position as a premier life sciences hub.
By Ian Rogers | October 10, 2024
| BioBuzz has been connecting the life science workforce since 2009. We’ve built an expansive community in the Mid-Atlantic with a national readership that spans from Massachusettes to Florida, and New York to California. For our next chapter, we’re building a proprietary talent logistics model to help employers source and hire life science talent. Learn more. |
Adare Pharma Solutions is a global technology-driven contract development and manufacturing organization (CDMO) that provides product development through commercial manufacturing expertise focused on oral dosage forms for the pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 65 products sold by customers in more than 100 countries globally.
About the New Headquarters and Funding
The Department of Community and Economic Development (DCED) has approved a funding proposal for Adare, which includes a $2.4 million Pennsylvania Industrial Development Authority (PIDA) loan, a $460,000 Pennsylvania First grant, and a $100,000 workforce development grant to train workers. Adare is expanding its Philadelphia manufacturing and packaging facilities, with a 175,000 sq. ft. location at 7722 Dungan Road and a 128,000 sq. ft. facility at 1100 Orthodox Street. The company is also relocating its headquarters from New Jersey to the Philadelphia site. A ribbon-cutting ceremony for the new HQ was held on September 20, attended by DCED Secretary Rick Siger. Adare is enthusiastic about the expansion and the creation of 115 new jobs in Philadelphia.
Adare Pharma CEO Tom Sellig commented on the move, “We are thrilled to announce the relocation of Adare’s global headquarters to Philadelphia. This move highlights the growing importance of both Pennsylvania and Philadelphia as a premier life sciences hub. We are especially grateful to Governor Josh Shapiro and the Governor’s Action Team for their invaluable support in making this relocation possible. Their commitment to fostering a strong business environment is helping companies like Adare continue to grow by providing access to top talent and key markets.”
Life Sciences in Pennsylvania
Josh Shapiro and his team have demonstrated their support for the Pennsylvania life sciences ecosystem with this move, but it is not an isolated occasion. In July, Shapiro and the General Assembly signed and passed a bill that mandated biomarker testing coverage. Not only did this provide access to testing for many Pennsylvania residents, but was also a boon for many companies. Incite Health Inc., a company leading the way in biomarker testing through its pharmacogenomic and immune system biomarker platforms, commended Shapiro at an event in July.
Upholding his quote from last year’s opening of One uCity Square, Shapiro is “all in on growing the life sciences industry in Pennsylvania”. His 10-year economic development strategy was released earlier this year, with a focus on building “vibrant and resilient regions”. Since taking office, Shapiro has secured over $2 billion in private-sector investments. One can only expect more growth this year and decade in Philadelphia and the Pennsylvania ecosystem.
